Demographic and Clinical Characteristics Associated With Familiarity, Interest, and Use of Integrative Therapies Among Patients With Breast Cancer.

"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Jincong Q. Freeman, Jori Sheade, Fangyuan Zhao, and Dezheng Huo declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Rita Nanda declared advisory board involvement with and research funding from Arvinas, AstraZeneca, BeyondSpring, Celgene, FujiFilm, Genentech/Roche, Gilead, Infinity, iTeos, Merck, OBI Pharma, OncoSec, Pfizer, Relay Therapeutics, SeaGen, Sun Pharma, and Taiho. Olufunmilayo Olopade declared financial relationships with CancerIQ, 54gnene, HealthWell Solutions, Tempus; research funding from Ayala Pharmaceuticals, Cepheid, Color Genomics, Novartis, and Roche/Genentech."

"Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was supported by a donation from the Iannessa family, the National Cancer Institute (P20CA233307), and the Breast Cancer Research Foundation (BCRF-22-071)."